Medicare approves $390.75 reimbursement for a blood test that predicts diabetic kidney disease up to four years early.

The U.S. CMS has set a $390.75 reimbursement rate for Proteomics International’s PromarkerD blood test, a finger-prick diagnostic that predicts diabetic kidney disease up to four years before symptoms, using protein and clinical biomarkers. The decision, assigning the test a PLA code, unlocks Medicare coverage and sets a benchmark for private insurers. With over 32 million Americans with diabetes and diabetic kidney disease costing $130 billion annually, the test’s 86% accuracy in predicting kidney decline offers potential for early intervention with proven therapies. The ruling accelerates Proteomics’ planned 2026 national rollout, supported by a CLIA-certified lab and efforts to secure broader insurer coverage. The announcement boosted the company’s share price by up to 29%, reflecting strong market confidence.